67 related articles for article (PubMed ID: 18906)
1. Action of classic and unusual neuroleptics on various behavioral apomorphine-induced effects.
Boissier JR; Puech AJ; Simon P
Adv Biochem Psychopharmacol; 1977; 16():631-4. PubMed ID: 18906
[No Abstract] [Full Text] [Related]
2. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
Worms P
Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
[No Abstract] [Full Text] [Related]
3. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
Biazzi A; Fregnan GB
Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
[No Abstract] [Full Text] [Related]
4. [Significance of the dopamine-blocking and m-choline-blocking components in the antiapomorphine action of neuroleptics].
Zharkovskiĭ AM; Langel IuL; Chereshka KS; Zharkovskaia TA
Biull Eksp Biol Med; 1987 Mar; 103(3):317-9. PubMed ID: 2881585
[TBL] [Abstract][Full Text] [Related]
5. 3-substituted-1,2-benzisoxazoles: novel antipsychotic agents.
Davis L; Effland RC; Klein JT; Dunn RW; Geyer HM; Petko WW
Drug Des Discov; 1992 Feb; 8(3):225-40. PubMed ID: 1356026
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic aspects of some behavioral effects of psychotropic drugs.
Melzacka M
Pol J Pharmacol Pharm; 1984; 36(2-3):117-36. PubMed ID: 6147827
[TBL] [Abstract][Full Text] [Related]
7. Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(3):327-30. PubMed ID: 8106091
[TBL] [Abstract][Full Text] [Related]
8. [The possible neurochemical mechanisms of the neuroleptic action of buspirone-like serotonin agonists].
Kharin NA; Dolzhenko AT; Titievskiĭ AV; Naletov SV
Eksp Klin Farmakol; 1993; 56(4):12-4. PubMed ID: 8106056
[TBL] [Abstract][Full Text] [Related]
9. Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs.
Kenny M; Leonard BE
J Neurosci Res; 1980; 5(4):291-8. PubMed ID: 6107385
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics.
Koek W; Colpaert FC
J Pharmacol Exp Ther; 1993 Oct; 267(1):181-91. PubMed ID: 7901392
[TBL] [Abstract][Full Text] [Related]
11. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
Cook L; Tam SW; Rohrbach KW
J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
[TBL] [Abstract][Full Text] [Related]
12. Two distinct classes of dopamine receptor mediating actions of antipsychotics: binding and behavioral studies.
Sokoloff P; Martres MP; Protais P; Costentin J; Schwartz JC
Adv Biochem Psychopharmacol; 1983; 36():163-73. PubMed ID: 6134435
[No Abstract] [Full Text] [Related]
13. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
[No Abstract] [Full Text] [Related]
14. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.
Zhang M; Ballard ME; Unger LV; Haupt A; Gross G; Decker MW; Drescher KU; Rueter LE
Behav Brain Res; 2007 Aug; 182(1):1-11. PubMed ID: 17570538
[TBL] [Abstract][Full Text] [Related]
15. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
Hyttel J
Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
[No Abstract] [Full Text] [Related]
16. Antagonism of the apomorphine-induced yawning by "atypical" neuroleptics.
Dubuc I; Protais P; Colboc O; Costentin J
Neuropharmacology; 1982 Nov; 21(11):1203-6. PubMed ID: 6129594
[TBL] [Abstract][Full Text] [Related]
17. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
[TBL] [Abstract][Full Text] [Related]
18. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
Christensen AV; Arnt J; Hyttel J; Svendsen O
Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
[TBL] [Abstract][Full Text] [Related]
19. Predictability and specificity of behavioral screening tests for neuroleptics.
Worms P; Lloyd KG
Pharmacol Ther B; 1979; 5(1-3):445-50. PubMed ID: 40263
[No Abstract] [Full Text] [Related]
20. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
